We'll know more about the company's medium-term prospects by the end of the year.

Recent commentary has highlighted CRISPR Therapeutics’ expanding gene-editing pipeline, including cardiovascular candidates like CTX310 and CTX320 and programs in type 1 diabetes, alongside fresh Buy ...

CRISPR Therapeutics' stock decline is likely influenced by Editas Medicine's struggles, but CRISPR remains a distinct and stronger company with a promising long-term outlook. CRISPR's strategic ...

ZUG, Switzerland and BOSTON, June 30, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious ...

There are plenty of reasons, though, to be bullish on the stock, not the least of which is its improved cash position. The ...

The last time The Lancet Microbe featured an Editorial on CRISPR was in November 2020, to mark that year’s Nobel Prize in Chemistry, jointly awarded to Emmanuelle Charpentier and Jennifer A Doudna for ...